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Intestinal Microbiota-Dependent Phosphatidylcholine
Metabolites, Diastolic Dysfunction, and Adverse Clinical
Outcomes in Chronic Systolic Heart Failure
W.H. WILSON TANG, MD, ZENENG WANG, PhD, KEVIN SHRESTHA, MD, ALLEN G. BOROWSKI, RDCS,
YUPING WU, PhD, RICHARD W. TROUGHTON, MBBS, ALLAN L. KLEIN, MD, AND STANLEY L. HAZEN, MD, PhD
ABSTRACT
Background: Trimethylamine N oxide (TMAO) has been linked to increased cardiovascular risk. We
aimed to determine the prognostic value of TMAO and its dietary precursors, choline and betaine, in heart
failure (HF).
Methods and Results: In 112 patients with chronic systolic HF with comprehensive echocardiographic
evaluation, we measured plasma TMAO, choline, and betaine by mass spectrometry. Median (interquartile
range) TMAO levels, choline, and betaine levels were 5.8 (3.6e12.1) mmol/L, 10.9 (8.4e14.0) mmol/L,
and 43.8 (37.1e53.0) mmol/L, respectively, and were correlated with each other (all P ! .0001 for
both). TMAO levels were significantly higher in patients with diabetes mellitus (9.4 [4.9e13.2] vs 4.8
[3.4e9.8] mmol/L; P 5 .005) and in subjects with New York Heart Association functional class III or
greater (7.0 [4.7e14.8] vs 4.7 [3.4e11.3] mmol/L; P 5 .02). Elevated TMAO, choline, and betaine levels
were each associated with higher plasma N terminal proeB type natriuretic peptide (NT proBNP) levels
and more advanced left ventricular diastolic dysfunction, but not systolic dysfunction or inflammatory and
endothelial biomarkers. Higher choline (hazard ratio [HR] 1.64, 95% CI 1.22e2.20; P 5 .001), betaine
(HR 1.51, 95% CI 1.10e2.08; P 5 .01), and TMAO (HR 1.48, 95% CI 1.10e1.96; P 5 .01) predicted
increased risk for 5 year adverse clinical events (death/transplantation). Only higher TMAO levels pre
dicted incident adverse clinical events independently from age, estimated glomerular filtration rate, mitral
E/septal Ea, and NT proBNP levels (HR 1.46, 95% CI 1.03e2.14; P 5 .03).
Conclusion: Elevated plasma TMAO, choline, and betaine levels are each associated with more advanced
left ventricular diastolic dysfunction and portend poorer long term adverse clinical outcomes in chronic
systolic HF. However, only higher plasma TMAO was associated with poor prognosis after adjustment
for cardiorenal indices. (J Cardiac Fail 2015;21:91e96)
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TMAO, Choline, and Betaine Assay
Quantification of TMAO, choline, and betaine was performed
with the use of stable isotope dilution liquid chromatography
with tandem mass spectrometry (LC/MS/MS), stable isotope dilu
tion assay, and high performance LC with online electrospray
ionization (ESI)/MS/MS on an AB Sciex Qtrap 5500 mass spec
trometer as previously described.8 Arginine metabolites (asym
metric dimethylarginine [ADMA], symmetric dimethylarginine
[SDMA], L arginine, L ornithine, and L citrulline) were quanti
fied with the use of stable isotope dilution LC/ESI/MS/MS assays
on an upgraded ABI 365 triple quadrupole mass spectrometer
(Applied Biosystems, Foster City, California) with Ionics EP
10þ redesigned source (Concord, Ontario, Canada) and ESI nee
dle connected to an Aria LX4 series multiplexed high
performance LC system with Flux pumps (Cohesive Technologies,
Franklin, Massachusetts), as previously described.7 Global argi
nine bioavailability ratio (GABR) was calculated as the ratio
between the substrates (L arginine) and the products (L ornithine
plus L citrulline) of nitric oxide production.9
Aminoterminal proeB type natriuretic peptide (NT proBNP)
levels were measured with the use of the Elecsys platform (Roche
Diagnostics, Indianapolis, Indiana).10 Plasma myeloperoxidase
(MPO) and high sensitivity C reactive protein (hsCRP) levels
were measured by means of CardioMPO assay (Cleveland Heart
Labs, Cleveland, Ohio)11 as well as N Latex Cystatin C Cardio
Phase assay (Siemens/Dade Behring, Deerfield, Illinois)12,13 as
previously described.
Statistical Analysis
Continuous variables were summarized as mean 6 SD if nor
mally distributed and median (interquartile range [IQR]) if non
normally distributed. Normality was assessed by means of the
Shapiro Wilk W test. Spearman rank correlation was used as a
nonparametric measure of association between metabolites and
dependent variables. Plasma levels of TMAO, choline, and betaine
were compared across categoric variables with the use of the Wil
coxon rank sum or Kruskal Wallis test. The optimal receiver oper
ating characteristic (ROC) curve cutoff value for plasma levels of
TMAO, choline, and betaine in predicting adverse clinical events
was chosen as the value maximizing sensitivity plus specificity.
Kaplan Meier survival plots were calculated from baseline to
time of adverse event and compared with the use of the log rank
test. Cox proportional hazards analysis were used to assess the
clinical risks associated with higher TMAO, choline, and/or
betaine levels, in which the proportional hazards assumption
was verified with log (time) versus log [ log (survival)] plots.
A 2 sided P value of !.05 was considered to be statistically sig
nificant. All analyses were performed with the use of JMP 10 Pro
(SAS, Cary, North Carolina).
Results
Table 1 illustrates the baseline characteristics of the
study population. Overall, the cohort was representative
of a stable outpatient cohort of patients with systolic heart
failure, with 40 (36%) experiencing at least New York
Heart Association (NYHA) functional class III symptoms.
Overall, TMAO correlated with choline (r 5 0.40;
P ! .0001) but not betaine (r 5 0.08; P 5 .43), and
choline correlated with betaine (r 5 0.46; P ! .0001).
Intestinal microbiota are implicated in the develop-
ment of metabolic phenotypes such as obesity and insulin 
resistance.1 With the use of an unbiased metabolomics 
approach, our group recently identified 3 metabolites of 
the dietary lipid phosphatidylcholine choline, betaine 
and the gut microbiota generated metabolite trimethyl-
amine-N-oxide (TMAO) that are associated with 
atherosclerotic cardiovascular disease.2 We recently vali-
dated those findings in a larger-scale clinical cohort 
whereby elevated plasma TMAO levels portend greater 
risk of major adverse cardiac events,3 and we showed 
the mechanistic link between TMAO and macrophage 
activation2 as well as alterations in cholesterol meta-
bolism and transport.4 Because choline and betaine are 
substrates in the formation of TMAO by intestinal micro-
biota, we have further demonstrated their prognostic 
values in predicting future major adverse cardiac events 
to be  largely driven by the presentation of elevated  
TMAO levels.5
Heart failure (HF) is a frequent adverse complication of 
atherosclerotic cardiovascular disease and may present 
either as myocardial ischemia, vascular dysfunction, and 
fibrosis leading to progressive diastolic dysfunction or as 
progressive myocyte damage and cardiac remodeling lead-
ing to systolic dysfunction. We recently reported the asso-
ciation between TMAO and long-term mortality risk in a 
large cohort of patients with a history of chronic HF, inde-
pendently from renal insufficiency or natriuretic peptide 
levels.6 However, the relationship between TMAO and its 
dietary precursors choline and betaine and myocardial 
and inflammatory indices, markers of endothelial dysfunc-
tion, as well as their relative prognostic values in patients 
with chronic systolic HF, has not yet been carefully 
explored. In the present study, our objective was to investi-
gate the relationship between the 3 phosphatidylcholine 
metabolites TMAO, choline, and betaine and myocardial 
indices, inflammatory and endothelial biomarkers, and 
long-term clinical prognosis in subjects with chronic sys-
tolic HF.
Materials and Methods
Study Population
This was a single center prospective cohort study approved by 
the Cleveland Clinic Institutional Review Board, and every subject 
provided written informed consent. We enrolled 112 ambulatory 
subjects $18 years of age with stable but symptomatic chronic 
systolic HF (left ventricular [LV] ejection fraction #35%;), who 
underwent comprehensive echocardiographic evaluation as part 
of a research study at the Cleveland Clinic. Subjects were 
excluded if they had significant primary valvular abnormalities. 
Comprehensive transthoracic echocardiographic evaluation of sys
tolic and diastolic myocardial performance was assessed as previ
ously described.7 The composite end point of adverse clinical 
events (all cause mortality and cardiac transplantation) was pro
spectively tracked for 5 years by telephone follow up and medical 
chart review.
Older patients were more likely to have higher levels of
choline, but not of betaine or TMAO. Meanwhile, men
had higher choline and betaine levels than women (P !
.001), yet levels were similar between those with versus
without diabetes. As expected, and as previously
described,2,3 those with a history of diabetes mellitus or
renal insufficiency had higher levels of TMAO, choline,
and betaine compared with those without. Interestingly,
there were no significant differences between TMAO,
choline, and betaine in those with ischemic versus noni-
schemic etiologies, nor across MPO or hsCRP levels
(Table 2). Also, those receiving loop diuretics had higher
TMAO but similar choline and betaine levels compared
with those not on loop diuretics (P ! .05).
The relationship between TMAO, choline, and betaine
levels and clinical, laboratory, and echocardiographic pa-
rameters are presented in Table 2. Interestingly, there
were statistically significant correlations between all the
metabolites and multiple echocardiographic indices. More-
over, we observed consistent positive correlations between
TMAO and indices of diastolic dysfunction, especially with
mitral E/septal Ea and left atrial volume index (Table 2). In
contrast, there were no statistically significant correlations
noted between TMAO, choline, and betaine in LV ejection
fraction or LV dimensions. Figure 1 demonstrates the
relationship between TMAO, choline, and betaine levels
stratified according to a mitral E/septal Ea cutoff at 15.
Meanwhile there was strong positive correlation between
methylated arginine metabolites and choline and to a lesser
extent betaine, and an inverse correlation was observed be-
tween both choline and betaine and GABR. In contrast,
TMAO did not correlate with any methylated arginine me-
tabolites, and only modestly with GABR. In multivariate
linear regression analysis with all variables, choline was
independently associated only with cystatin C (b 5 0.40;
P ! .0001) and GABR (b 5 0.39; P ! .0001), betaine
only with GABR (b 5 0.31; P 5 .002) and right ventric-
ular systolic dysfunction class (b 5 0.21; P 5 .030), and
TMAO only with NT-proBNP (b 5 0.34; P 5 .003) and
cystatin C (b 5 0.75; P ! .0001).
Table 3 presents the Cox proportional hazard models of
TMAO, choline, and betaine for long-term adverse clinical
outcomes. There was a total of 40 events over 5 years of
follow-up. All 3 measures (choline, betaine, and TMAO)
were predictive of the composite end point of 5-year all-
cause mortality plus cardiac transplantation. However,
only the prognostic value of TMAO remained statistically
significant after adjustments for age, estimated glomerular
filtration rate (eGFR), mitral E/septal Ea, and NT-proBNP
levels (adjusted hazard ratio 1.46, 95% confidence interval
1.03 2.14; P 5 .031). When stratified according to the
optimal ROC cutoff value of 6.1 mmol/L for TMAO and
median NT-proBNP (1,473 pg/mL) for this cohort, the sub-
set of patients with both elevated TMAO and NT-proBNP
demonstrated the greatest risk of future adverse cardiac
events (Fig. 2).
Table 1. Baseline Characteristics
Variable Value
Age, y 57 6 14
Male 84 (75%)
Ischemic etiology 48 (43%)
History of diabetes mellitus 32 (29%)
Echocardiographic indices
Left ventricular end diastolic volume,
indexed (mL/m2)
111 6 36
Left ventricular ejection fraction (%) 26 6 6
Diastolic stage III 44 (40%)
Mitral regurgitation $3þ 11 (10%)
Right ventricular systolic pressure (mm Hg) 34 6 13
Right ventricular systolic dysfunction $3þ 31 (28%)
Left atrial volume index (mL/m2) 42 6 15
Mitral E/septal Ea 19 6 12
Medications
Angiotensin converting enzyme inhibitor or
angiotensin receptor blockers
103 (94%)
Beta blocker 66 (60%)
Spironolactone 31 (30%)
Loop diuretics 87 (78%)
Laboratory data
Estimated glomerular filtration rate
(mL min 1 1.73 m 2)
70 6 26
N Terminal proeB type natriuretic
peptide (pg/mL)
1,473 (543e3,438)
Myeloperoxidase (pg/mL) 312 (263e427)
High sensitivity C reactive protein (mg/L) 3.33 (1.55e6.81)
Cystatin C (mg/dL) 1.23 (1.03e1.66)
Aysmmetric dimethylarginine (mmol/L) 0.43 (0.36e0.55)
Symmetric dimethylarginine (mmol/L) 0.29 (0.23e0.39)
Global arginine bioavailability ratio 0.76 (0.55e1.03)
Choline (mmol/L) 10.9 (8.4e14.0)
Betaine (mmol/L) 43.8 (37.1e53.0)
Trimethylamine N oxide (mmol/L) 5.8 (3.6e12.1)
Values are presented as mean 6 SD, n (%), or median (interquartile
range).
Table 2. Univariate Correlations Between
Gut FloraeDependent Phosphatidylcholine Metabolites
and Clinical and Echocardiographic Indices
Variable Choline Betaine TMAO
Age 0.26** 0.09 0.12
Left ventricular end diastolic
volume, indexed
0.12 0.09 0.06
Left ventricular ejection fraction 0.10 0.19 0.09
Mitral regurgitation 0.20* 0.13 0.05
Right ventricular systolic
pressure
0.34** 0.28** 0.14
Right ventricular systolic
dysfunction
0.29** 0.34*** 0.05
Mitral E/septal Ea 0.33** 0.29* 0.29**
Left atrial volume index 0.45** 0.22* 0.29**
Aminoterminal pro B type
natriuretic peptide
0.45** 0.27** 0.26**
Myeloperoxidase 0.03 0.04 0.11
High sensitivity C reactive
protein
0.01 0.14 0.19
Cystatin C 0.54**** 0.24* 0.40****
Estimated glomerular
filtration rate
0.39**** 0.13 0.36***
Asymmetric dimethylarginine 0.33*** 0.20* 0.11
Symmetric dimethylarginine 0.39**** 0.13 0.18
Global arginine
bioavailability ratio
0.54**** 0.37**** 0.23*
TMAO, trimethylamine N oxide.
*P ! .05; **P ! .01; ***P ! .001; ****P ! .0001.
Discussion
We recently reported the association between elevated
TMAO levels and increased 5-year mortality risk indepen-
dently from cardiorenal indices in a large cohort of patients
with a history of HF.6 In the present study, we validated our
findings in an independent cohort of ambulatory patients
with chronic systolic HF, with added insights into the rela-
tionship between all 3 phosphatidylcholine metabolites,
TMAO, choline, and betaine, and both echocardiographic
determinants and renal and inflammatory biomarkers.
There are several notable findings. First, we observed a
stronger prognostic value in TMAO than in choline and
betaine in patients with chronic systolic HF, which was in-
dependent from cardiorenal indices. Second, we observed
correlations between all 3 metabolites and LV diastolic
dysfunction rather than LV systolic dysfunction. Third,
the relatively lack of correlations between TMAO, choline,
and betaine and several well known inflammatory bio-
markers and differential relationships with markers of
endothelial dysfunction also suggested an independent
pathophysiologic pathway. Of note, the higher level of
TMAO found in subjects with renal insufficiency or
diabetes mellitus points to an underlying metabolic defect
relevant to those disease states rather than a systemic in-
flammatory response. Nonetheless, the association between
elevated TMAO and both HF severity and incident adverse
outcomes independent of other cardiorenal indices argues
for a potential pathogenic mechanistic link between the
gut microbiota pathway generating TMAO and HF devel-
opment and/or progression. Of note, this was a cohort of
ambulatory stable HF patients with LV systolic dysfunc-
tion, with an annualized mortality of 7.1% (assuming trans-
plantation as equivalent as death), which was not too
different from other reported clinical trials. Taken together,
these findings provided validation of the clinical signifi-
cance of TMAO levels in HF6 and suggest that more studies
are warranted to understand the mechanistic underpinnings
of the association.
A mechanistic link between altered intestinal microbiota
and myocardial function has previously been suggested to
Fig. 1. Relationship between intestinal microfloraedependent phosphatidylcholine metabolites and diastolic dysfunction in chronic systolic
heart failure. TMAO, trimethylamine N oxide.
Table 3. Cox Proportional Hazard Analyses of Adverse
Clinical Outcomes
Variable Hazard Ratio* (95% CI) P Value
Choline
Unadjusted 1.64 (1.22e2.20) .001
Adjusted 1.22 (0.82e1.85) .333
Betaine
Unadjusted 1.51 (1.10e2.08) .011
Adjusted 1.33 (0.93e1.89) .115
Trimethylamine N oxide (TMAO)
Unadjusted 1.48 (1.10e1.96) .010
Adjusted 1.46 (1.03e2.14) .031
CI, confidence interval.
Adjusted for age, estimated glomerular filtration rate, mitral E/septal Ea,
and N terminal proeB type natriuretic peptide.
*Hazard ratios per 1 standard deviation (Ln Choline 0.38 mmol/L; Ln
Betaine 0.27 mmol/L; Ln TMAO 0.99 mmol/L).
Fig. 2. Kaplan Meier survival curve stratified according to levels
of trimethylamine N oxide (TMAO) and N terminal proeB type
natriuretic peptide (NT proBNP) levels. /þ TMAO, below
versus above 6.1 mmol/L; /þ NT proBNP, below versus above
1,473 pg/mL (median).
result largely in the setting of responses to circulatory
insult.14,15 Dysbiosis (abnormal changes in intestinal mi-
crobiota composition) has also been reported in rodent
models of myocardial infarction.11 Interestingly, supple-
mentation with a probiotic was reported to be associated
with improved cardioprotection in a surgical model of
myocardial infarction in a recent study.16 The present anal-
ysis is the 1st human study to our knowledge to report the
relationship between the intestinal microbiota-dependent
analyte TMAO and its dietary precursors, choline and
betaine, with echocardiographic indices in the setting of
chronic systolic HF. Of note, there was no demonstrable
relationship between TMAO, choline, or betaine and LV
systolic function or degree of cardiac remodeling. Rather,
the stronger correlations observed were between all 3 me-
tabolites and LV diastolic functional indices (Table 2).
These observations suggest that a greater degree of ‘‘back-
ward failure’’ (congestion, with either scarring or ischemia)
rather than ‘‘forward failure’’ (impaired perfusion) may be
associated with the primary metabolic defect driving the
observed associations. Consistently with this, associations
with renal functional indices were noted for choline and
TMAO, but again, the association between TMAO and
adverse events among subjects remained even after adjust-
ments for renal function.
Another possibility for the association with elevated
TMAO levels among subjects with poorer prognosis may
arise because of the greater degree of intestinal congestion
from right-sided HF. Indeed, it is tempting to speculate that
such congestion and attendant intestinal edema could lead
to alterations in intestinal microbiota composition that
adversely affects (enhances) TMAO production.17 Earlier
investigations have observed a reduction in active carrier-
mediated intestinal transport processes in decompensated
HF, leading to epithelial dysfunction possibly as a conse-
quence of intestinal ischemia.18 As intestinal microbiota
shift rapidly from ischemia to reperfusion,19 it is conceiv-
able that the balance and amount of intestinal commensal
versus pathobiontic bacteria may also be affected by venous
congestion, thereby leading to altered metabolic milieu and
downstream metabolic derangements for the host. There-
fore, how HF itself affects intestinal microbial composition
and function, and conversely, how intestinal microbiota
directly or indirectly affect the HF phenotype and patho-
physiology, should be further explored.
The lack of relationship between TMAO and its dietary
precursors, choline and betaine, and inflammatory bio-
markers is also somewhat unexpected, because earlier
studies implied that the lack of intestinal microbiota may
be associated with a state of active interleukin-10
mediated inflammatory hyporesponsiveness.20 That being
said, our previous studies in a broad population of cardiac
patients also demonstrated prognostic value of TMAO be-
ing independent from plasma MPO levels.3 This is perhaps
not too surprising in our cohort of ambulatory chronic sys-
tolic HF patients, where organ perfusion remains largely
preserved. Therefore, our present findings may imply
concepts beyond the traditional gut hypothesis, whereby
reduced circulatory efficiency in the HF setting leads to
impaired barrier function of the intestinal epithelia and
heightened inflammatory responses to endotoxins and
peptidoglycans.21 The dissociation between TMAO and
choline/betaine regarding relationships with markers of
endothelial dysfunction further suggests that the metabolic
defect associated with elevated TMAO may even be inde-
pendent from traditional measures of vascular dysfunction
that have been known to impact diastolic dysfunction.7,9
What are the implications of these findings? First, under-
standing why patients with advancing systolic HF have
increased levels of TMAO will be important. Although
increased production (from increased dietary sources or mi-
crobial/host enzymes) or reduced clearance (because of
renal insufficiency) may contribute, there is a need to
further determine if the underlying cardiac insufficiency
or metabolic defects associated with cardiac dysfunction
may contribute to such a phenomenon. The independence
of the association between elevated TMAO levels and
poor outcomes after adjustments for cardiorenal indices
such as eGFR and NT-proBNP argues for additional under-
lying mechanistic links. Second, neither dietary nor intesti-
nal microbiota influences on HF pathophysiology have
been well studied, even though the ‘‘gut hypothesis’’ of
heart failure has been well established in the literature.
Further studies are needed to determine if manipulation
of gut microbiota composition or dietary modifications
(similar to a renal or diabetic diet) may offer novel thera-
peutic approaches in the setting of elevated TMAO levels
in patients with HF. Indeed, a low-protein diet, which is
typical for patients with chronic kidney disease, is antici-
pated to be low in dietary nutrients such as carnitine,
choline, and phosphatidylcholine that can generate
TMAO.4,5 Nutritional and microbiota-associated metabolic
factors that can lead to the causation, development, and pro-
gression of myocardial dysfunction may therefore provide
important therapeutic targets in a disease with grave
morbidity and mortality for which treatment has largely
focused on hemodynamic augmentation and neurohor-
monal suppression.
Study Limitation
There are several limitations in this single tertiary
referral center experience. Our earlier studies were largely
confined to measurements of fasting samples of phosphati-
dylcholine metabolites, whereas samples in the present
study were collected without an overnight fast. Neverthe-
less, data from our previous studies suggested that the over-
all plasma TMAO, choline, and betaine levels, although
fluctuating shortly after feeding, appear to stay within a
confined range.3 Furthermore, we did not have any informa-
tion or measurements regarding the dietary habits (espe-
cially dietary phosphatidylcholine amounts ingested) of
our subjects, nor did we have any quantification of intes-
tinal microbiota composition, intestinal barrier function,
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or commensal versus pathobiontic bacterial growth. We also
did not have independently adjudicated NYHA func-tional
class (the majority of patients were symptomatic in NYHA
functional class II III), physical exam findings, or
electrocardiographic data at the time of evaluation for the
study, and the relatively low number of adverse events (n 5
40) may have limited our multivariate analysis.
Conclusion
Elevated plasma TMAO, choline, and betaine levels are
each associated with more advanced LV diastolic dysfunc-
tion and portend poorer long-term adverse clinical out-
comes in chronic systolic HF. However, only higher
plasma TMAO levels were associated with poor prognosis
after adjustment for cardiorenal indices.
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